Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies

Metastatic basal cell cancer (BCC) is an ultra-rare malignancy with no approved therapies beyond Hedgehog inhibitors. We characterized the genomics, tumor mutational burden (TMB), and anti-PD-1 therapy responses in patients with locally advanced or metastatic BCC. Overall, 2,039 diverse cancer sampl...

Full description

Bibliographic Details
Main Authors: Aaron M. Goodman, Shumei Kato, Philip R. Cohen, Amélie Boichard, Garrett Frampton, Vincent Miller, Philip J. Stephens, Gregory A. Daniels, Razelle Kurzrock
Format: Article
Language:English
Published: Taylor & Francis Group 2018-03-01
Series:OncoImmunology
Subjects:
basal cell carcinoma
immunotherapy
tumor mutational burden
pd-1
pd-l1
checkpoint blockade
biomarkers
therapeutic antibodies
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1404217

Internet

http://dx.doi.org/10.1080/2162402X.2017.1404217

Similar Items